RayKnowChina Research Map
Shortlist

Not yet recruitingBreast cancerPhase 2

Registered title, quoted from ClinicalTrials.gov

Evaluation of Neoadjuvant Therapy With Trastuzumab, Pertuzumab, Docetaxel, and QL1706 in Early or Locally Advanced HER2+ Breast Cancer

An open trial on breast cancer, registered on ClinicalTrials.gov. Led by Tianjin Medical University Cancer Institute & Hospital; 4 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 5

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorTianjin Medical University Cancer Institute & Hospital天津医科大学肿瘤医院TianjinHospital page
  2. Study siteFirst Affiliated Hospital of Henan University of Science and Technology河南科技大学第一附属医院LuoyangHospital page
  3. Study siteFirst Affiliated Hospital of Sun Yat-sen University中山大学附属第一医院GuangzhouHospital page
  4. Study siteFourth Hospital of Hebei Medical University河北医科大学第四医院ShijiazhuangHospital page
  5. Study siteGuangdong Provincial People's Hospital广东省人民医院GuangzhouHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07246317, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 8

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (8 points)Hide the checklist
  1. 18 years to 70 years; sex: women only

    Registered eligibility fields

  2. Histologically/cytologically confirmed primary breast cancer.

    Inclusion criterion 4

  3. AJCC 8th edition Stage II-IIIC (T2-T4 any N, or any T N1-3 M0) unilateral invasive breast cancer.

    Inclusion criterion 6

    Other malignancies within 3 years, except: those treated with surgery alone and disease-free for 5 years; cured cervical carcinoma in situ, non-melanoma skin cancer, or superficial bladder cancer [Ta, Tis, T1].

    Exclusion criterion 3

    Myocardial ischemia/infarction (≥Grade 2), arrhythmias (QTc≥450ms M, ≥470ms F), or CHF (≥NYHA Class II).

    Exclusion criterion 13

  4. For women of childbearing potential: negative pregnancy test within 7 days prior to treatment; must not be breastfeeding.

    Inclusion criterion 16

    Use of highly effective contraception during and for 3 months after treatment.

    Inclusion criterion 17

    Prior anti-tumor therapy (chemotherapy, endocrine, anti-HER2) or breast surgery for breast cancer within 3 years (excluding diagnostic biopsy).

    Exclusion criterion 4

    Use of Chinese patent medicines with approved anti-tumor indications within 2 weeks prior to treatment.

    Exclusion criterion 16

  5. ECOG PS 0-1; life expectancy >6 months.

    Inclusion criterion 3

  6. ANC ≥1.5×10⁹/L; PLT ≥100×10⁹/L; HGB ≥90 g/L

    Inclusion criterion 12

    Creatinine ≤1.5×ULN

    Inclusion criterion 14

    PT/APTT/INR ≤1.5×ULN (or within therapeutic range if on anticoagulants)

    Inclusion criterion 15

    Active infection, unexplained fever ≥38.5°C within 7 days, or baseline WBC >15×10⁹/L.

    Exclusion criterion 24

  7. At least one measurable lesion per RECIST 1.1.

    Inclusion criterion 8

  8. Active HCV (RNA+), HIV+, syphilis (unless cured), or HBV (HBsAg+ with HBV DNA≥2000 IU/ml or positive qualitative test).

    Exclusion criterion 15

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: pregnancy, breastfeeding and contraception.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07246317, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Signed informed consent and compliant.
  • Age 18-70 years.
  • ECOG PS 0-1; life expectancy >6 months.
  • Histologically/cytologically confirmed primary breast cancer.
  • Primary tumor >2cm (by local standard assessment) or node-positive disease.
  • AJCC 8th edition Stage II-IIIC (T2-T4 any N, or any T N1-3 M0) unilateral invasive breast cancer.
  • Confirmed HER2-positive (IHC 3+ or ISH positive). Note: Patients with HER2-negative primary tumor but HER2-positive nodes are eligible.
  • At least one measurable lesion per RECIST 1.1.
  • Agreement to undergo surgery if indicated after neoadjuvant therapy.
  • Willing to provide tumor tissue for biomarker analysis.
  • Adequate organ function:
  • ANC ≥1.5×10⁹/L; PLT ≥100×10⁹/L; HGB ≥90 g/L
  • Albumin ≥30 g/L

-. TBIL ≤1.5×ULN; ALT/AST ≤2.5×ULN (≤5×ULN if liver metastases); AKP ≤2.5×ULN

  • Creatinine ≤1.5×ULN
  • PT/APTT/INR ≤1.5×ULN (or within therapeutic range if on anticoagulants)
  • For women of childbearing potential: negative pregnancy test within 7 days prior to treatment; must not be breastfeeding.
  • Use of highly effective contraception during and for 3 months after treatment.

Exclusion Criteria:

  • Stage IV metastatic breast cancer or patients deemed ineligible for curative surgery after neoadjuvant therapy.
  • Inflammatory breast cancer.
  • Other malignancies within 3 years, except: those treated with surgery alone and disease-free for 5 years; cured cervical carcinoma in situ, non-melanoma skin cancer, or superficial bladder cancer [Ta, Tis, T1].
  • Prior anti-tumor therapy (chemotherapy, endocrine, anti-HER2) or breast surgery for breast cancer within 3 years (excluding diagnostic biopsy).
  • Major surgery or significant traumatic injury within 28 days before treatment (excluding diagnostic biopsy).
  • Active or history of autoimmune diseases (e.g., autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hypophysitis, vasculitis, nephritis, hyperthyroidism). Exceptions: vitiligo, childhood asthma in complete remission without intervention in adulthood.
  • Current use of immunosuppressants or systemic corticosteroids (>10mg/day prednisone equivalent) within 2 weeks prior to enrollment.
  • History of severe hypersensitivity to monoclonal antibodies.
  • Known central nervous system metastases.
  • Poorly controlled concurrent illnesses, including:
  • Uncontrolled hypertension (SBP>150 or DBP>100 mmHg on medication) or history of hypertensive crisis/encephalopathy.
  • History of heart failure or systolic dysfunction (LVEF <55%).
  • Myocardial ischemia/infarction (≥Grade 2), arrhythmias (QTc≥450ms M, ≥470ms F), or CHF (≥NYHA Class II).
  • Angina requiring medication; clinically significant valvular disease.
  • Active HCV (RNA+), HIV+, syphilis (unless cured), or HBV (HBsAg+ with HBV DNA≥2000 IU/ml or positive qualitative test).
  • Use of Chinese patent medicines with approved anti-tumor indications within 2 weeks prior to treatment.
  • Significant bleeding tendency or clinical bleeding within 3 months; positive fecal occult blood requiring gastroscopy if persistently positive.
  • Tumor invasion or high risk of invasion into major vessels, potentially causing fatal hemorrhage.
  • Pleural, peritoneal, or pericardial effusion requiring drainage (eligible if stable after drainage).
  • Arterial/venous thromboembolic events within 6 months (e.g., CVA, TIA, DVT, PE).
  • Known hereditary or acquired bleeding/thrombotic tendencies (e.g., hemophilia).
  • Severe, non-healing wounds, active ulcers, or untreated fractures.
  • Urinary protein ≥++ confirmed by 24-hour urine protein >1.0g.
  • Active infection, unexplained fever ≥38.5°C within 7 days, or baseline WBC >15×10⁹/L.
  • History of drug abuse or psychiatric disorders.
  • Participation in other anti-tumor drug trials within 4 weeks.
  • Allergy to any study drug or its components.
  • Any condition deemed by the investigator to pose a safety risk or affect study completion.

Quoted from ClinicalTrials.gov, NCT07246317, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07246317, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07246317